ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT)
CUSIP: 77313F106
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 109,265,652
- Total 13F shares
- 96,588,463
- Share change
- +1,656,151
- Total reported value
- $314,789,902
- Put/Call ratio
- 92%
- Price per share
- $3.26
- Number of holders
- 171
- Value change
- +$10,465,360
- Number of buys
- 88
- Number of sells
- 111
Quarterly Holders Quick Answers
What is CUSIP 77313F106?
CUSIP 77313F106 identifies RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 77313F106:
Top shareholders of RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
3/4/5
13F
|
Director, Other*, 10%+ Owner · Company |
—
mixed-class rows
|
21,763,079
mixed-class rows
|
$100,686,510 | — | 19 Sep 2025 | |
| Roderick Wong |
3/4/5
|
Director, 10%+ Owner |
17%
|
18,236,124
|
$44,689,444 | — | 18 Jun 2025 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
7.7%
|
8,363,813
|
$20,491,342 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.8%
|
7,428,676
|
$18,200,255 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.6%
|
6,122,461
|
$15,000,030 | — | 30 Jun 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.8%
|
4,143,333
|
$10,151,166 | — | 30 Jun 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
3.6%
|
3,903,081
|
$9,562,548 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
— |
0.9%
|
1,004,476
|
$7,895,181 | -$48,317,346 | 30 May 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.9%
|
3,169,036
|
$7,764,138 | — | 30 Jun 2025 | |
| Kinnari Patel |
3/4/5
|
President, Head of R&D and Chief Operating Officer |
—
mixed-class rows
|
745,842
mixed-class rows
|
$6,417,297 | -$14,142 | 20 May 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.1%
|
2,348,837
|
$5,754,651 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
2,030,891
|
$4,976,499 | — | 30 Jun 2025 | |
| Newtyn Management, LLC |
13F
|
Company |
1.8%
|
2,000,000
|
$4,900,000 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
1,943,690
|
$4,762,041 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.6%
|
1,725,360
|
$4,227,132 | — | 30 Jun 2025 | |
| Prosight Management, LP |
13F
|
Company |
1.4%
|
1,580,588
|
$3,872,441 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.4%
|
1,575,468
|
$3,859,897 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.4%
|
1,548,262
|
$3,793,242 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.4%
|
1,490,251
|
$3,651,115 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.1%
|
1,207,802
|
$2,959,114 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1%
|
1,099,829
|
$2,696,000 | — | 30 Jun 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
1%
|
1,100,000
|
$2,695,000 | — | 30 Jun 2025 | |
| Gotham Makker |
3/4/5
|
Director |
—
mixed-class rows
|
1,037,149
mixed-class rows
|
$2,545,450 | — | 18 Jun 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.91%
|
992,825
|
$2,432,421 | — | 30 Jun 2025 | |
| Aaron Ondrey |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
262,815
mixed-class rows
|
$2,394,410 | -$4,257 | 03 Jul 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.78%
|
850,000
|
$2,082,500 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.77%
|
836,508
|
$2,049,445 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.71%
|
777,668
|
$1,905,286 | — | 30 Jun 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.66%
|
718,781
|
$1,761,013 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.64%
|
701,337
|
$1,718,275 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.6%
|
652,865
|
$1,599,519 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.58%
|
638,515
|
$1,564,363 | — | 30 Jun 2025 | |
| Mark Andrew White |
3/4/5
|
General Manager, Commercial Affairs |
—
mixed-class rows
|
101,867
mixed-class rows
|
$1,560,177 | — | 31 Oct 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.57%
|
624,303
|
$1,529,542 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.56%
|
614,761
|
$1,506,164 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
0.54%
|
591,263
|
$1,448,594 | — | 30 Jun 2025 | |
| Walleye Capital LLC |
13F
|
Company |
—
mixed-class rows
|
1,218,898
mixed-class rows
|
$1,436,653 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.51%
|
559,950
|
$1,372,080 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.51%
|
552,079
|
$1,352,594 | — | 30 Jun 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.46%
|
500,000
|
$1,225,000 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.43%
|
467,105
|
$1,144,407 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.42%
|
461,374
|
$1,130,366 | — | 30 Jun 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.4%
|
432,760
|
$1,120,848 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.42%
|
454,640
|
$1,113,868 | — | 30 Jun 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
0.41%
|
452,767
|
$1,109,279 | — | 30 Jun 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.4%
|
437,295
|
$1,071,373 | — | 30 Jun 2025 | |
| Carlos Garcia-Parada |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
71,328
mixed-class rows
|
$1,068,080 | — | 14 Feb 2022 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.4%
|
434,409
|
$1,064,302 | — | 30 Jun 2025 | |
| M28 Capital Management LP |
13F
|
Company |
0.35%
|
385,680
|
$944,916 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.35%
|
377,796
|
$925,000 | — | 30 Jun 2025 |
Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) as of Q3 2025
As of 30 Sep 2025,
ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) was held by
171 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
96,588,463 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, MAVERICK CAPITAL LTD, BlackRock, Inc., VANGUARD GROUP INC, MPM BIOIMPACT LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, MILLENNIUM MANAGEMENT LLC, Monaco Asset Management SAM, and Newtyn Management, LLC.
This page lists
171
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
194
Q3 2025 holders
171
Holder diff
-23
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.